Sugi Predict

Sugi Predict / Compounds / SCHEMBL4186738

SCHEMBL4186738

SCHEMBL4186738

CCC(=O)N[C@H](C(=O)O)[C@@H](C)CC

nearest known ligand 0.63

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
▸ ALDH1A1 P00352 1/20 0.63
▸ L3MBTL1 Q9Y468 1/20 0.54
▸ FPR2 P25090 3/20 0.47
▸ KMT2A Q03164 2/20 0.47
▸ MEN1 O00255 1/20 0.47
▸ ATM Q13315 1/20 0.47
▸ CA2 P00918 3/20 0.45
▸ CA1 P00915 2/20 0.45
▸ ENPEP Q07075 2/20 0.43
▸ CYP2C9 P11712 2/20 0.43
▸ MAPK1 P28482 1/20 0.43
▸ CYP2C19 P33261 1/20 0.43
▸ MME P08473 1/20 0.43
▸ ACE P12821 1/20 0.43
▸ CPA1 P15085 1/20 0.43
▸ ACE2 Q9BYF1 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4186736 1.00 ALDH1A1 (0.63) ALDH1A1L3MBTL1FPR2KMT2AMEN1
SCHEMBL6307436 0.86 ALDH1A1 (0.61) ALDH1A1L3MBTL1FPR2KMT2AMEN1
SCHEMBL6307443 0.86 ALDH1A1 (0.61) ALDH1A1L3MBTL1FPR2KMT2AMEN1
SCHEMBL935682 0.84 ALDH1A1 (0.59) ALDH1A1L3MBTL1FPR2KMT2AMEN1
SCHEMBL21274505 0.84 ALDH1A1 (0.59) ALDH1A1L3MBTL1FPR2KMT2AMEN1
SCHEMBL23408841 0.84 ALDH1A1 (0.59) ALDH1A1L3MBTL1FPR2KMT2AMEN1
SCHEMBL935683 0.84 ALDH1A1 (0.59) ALDH1A1L3MBTL1FPR2KMT2AMEN1
SCHEMBL21274507 0.84 ALDH1A1 (0.59) ALDH1A1L3MBTL1FPR2KMT2AMEN1
SCHEMBL2377759 0.84 ALDH1A1 (0.59) ALDH1A1L3MBTL1FPR2KMT2AMEN1
SCHEMBL6136316 0.84 ALDH1A1 (0.59) ALDH1A1L3MBTL1FPR2KMT2AMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090186853-A1 COMPOSITIONS COMPRISING N-PROPANOYL DERIVATIVES OF AMINO ACIDS, AMINOCARBOHYDRATES AND DERIVATIVES THEREOF YU RUEY J 2009-07-23 — — US claimed
EP-1865953-A4 COMPOSITION COMPRISING N-PROPANOYL DERIVATIVES OF AMINO ACIDS, AMINOCARBOHYDRATES AND DERIVATIVES THEREOF YU RUEY J (US) 2008-04-30 — — EP claimed
EP-1865953-A2 COMPOSITION COMPRISING N-PROPANOYL DERIVATIVES OF AMINO ACIDS, AMINOCARBOHYDRATES AND DERIVATIVES THEREOF Yu, Ruey J., Dr. (US) 2007-12-19 — — EP claimed
WO-2006101940-A2 COMPOSITION COMPRISING N-PROPANOYL DERIVATIVES OF AMINO ACIDS, AMINOCARBOHYDRATES AND DERIVATIVES THEREOF YU, RUEY, J. (US) 2006-09-28 — — WO claimed
US-20060211754-A1 Compositions comprising N-propanoyl derivatives of amino acids, aminocarbohydrates and derivatives thereof YU RUEY J 2006-09-21 — — US claimed
US-20050171194-A1 Enlargement of mucocutaneous or cutaneous organs and sites with topical compositions YU RUEY J (US) 2005-08-04 — — US claimed
WO-2005055947-A2 ENLARGEMENT OF MUCOCUTANEOUS OR CUTANEOUS ORGANS AND SITES WITH TOPICAL COMPOSITIONS YU RUEY J (US) 2005-06-23 — — WO claimed
EP-0946499-B1 N-(ARYL/HETEROARYL/ALKYLACETYL) AMINO ACID AMIDES, PHARMACEUTICAL COMPOSITIONS COMPRISING SAME, AND METHODS FOR INHIBITING BETA-AMYLOID PEPTIDE RELEASE AND/OR ITS SYNTHESIS BY USE OF SUCH COMPOUNDS ELAN PHARM INC (US) 2005-06-01 — — EP claimed
CN-116546988-A Prodrugs of 5α -hydroxy-6β - [2- (1H-imidazol-4-yl) ethylamino ] cholestan-3β -ol and pharmaceutical compositions for cancer treatment containing the same 登德罗杰尼克斯公司 2023-08-04 — — CN disclosed
US-9839665-B2 Aminostatin derivatives for the treatment of arthrosis MERCK PATENT GMBH (DE) 2017-12-12 — — US disclosed
US-20160228493-A1 AMINOSTATIN DERIVATIVES FOR THE TREATMENT OF ARTHROSIS MERCK PATENT GMBH (DE) 2016-08-11 — — US disclosed
US-9345742-B2 Aminostatin derivatives for the treatment of arthrosis MERCK PATENT GMBH (DE) 2016-05-24 — — US disclosed
US-20090186853-A1 COMPOSITIONS COMPRISING N-PROPANOYL DERIVATIVES OF AMINO ACIDS, AMINOCARBOHYDRATES AND DERIVATIVES THEREOF YU RUEY J 2009-07-23 — — US disclosed
EP-1865953-A4 COMPOSITION COMPRISING N-PROPANOYL DERIVATIVES OF AMINO ACIDS, AMINOCARBOHYDRATES AND DERIVATIVES THEREOF YU RUEY J (US) 2008-04-30 — — EP disclosed
EP-0521827-B1 Pharmacological active hydrazin derivatives and process for their preparation CIBA GEIGY AG (CH) 1996-09-25 — — EP disclosed
EP-0604368-B1 Anti retroviral hydrazine derivatives CIBA GEIGY AG (CH) 1996-09-18 — — EP disclosed
CN-1093701-A Antiretroviral hydrazine derivative CIBA GEIGY AG (CH) 1994-10-19 — — CN disclosed
EP-0604368-A1 Anti retroviral hydrazine derivatives CIBA-GEIGY AG (CH) 1994-06-29 — — EP disclosed
CN-1068333-A Has hydrazine analog derivative of pharmacologically active and preparation method thereof CIBA GEIGY AG (CH) 1993-01-27 — — CN disclosed
EP-0521827-A1 Pharmacological active hydrazin derivatives and process for their preparation CIBA-GEIGY AG (CH) 1993-01-07 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160228493-A1 AMINOSTATIN DERIVATIVES FOR THE TREATMENT OF ARTHROSIS CTSD, CTSB, CTSZ ALDH1A1 2943/4885L3MBTL1 2430/4885FPR2 827/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.